Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710869 | 1.00 | ADORA1 (0.45) | ADORA1ESR2NR1H2HPGDMEN1 | |
| SCHEMBL4710868 | 1.00 | ADORA1 (0.45) | ADORA1ESR2NR1H2HPGDMEN1 | |
| SCHEMBL30793314 | 0.96 | ADORA1 (0.44) | ADORA1ESR2NR1H2HPGDMEN1 | |
| SCHEMBL2355722 | 0.92 | ADORA1 (0.52) | ADORA1ESR2NR1H2MEN1KMT2A | |
| SCHEMBL22679830 | 0.92 | ADORA1 (0.52) | ADORA1ESR2NR1H2MEN1KMT2A | |
| SCHEMBL1900963 | 0.92 | ADORA1 (0.52) | ADORA1ESR2NR1H2MEN1KMT2A | |
| SCHEMBL29052706 | 0.90 | ADORA1 (0.45) | ADORA1ESR2HPGDMEN1KMT2A | |
| SCHEMBL5379779 | 0.90 | ADORA1 (0.45) | ADORA1ESR2HPGDMEN1KMT2A | |
| SCHEMBL5379778 | 0.90 | ADORA1 (0.45) | ADORA1ESR2HPGDMEN1KMT2A | |
| SCHEMBL424706 | 0.88 | ESR2 (0.43) | ADORA1ESR2NR1H2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-03-06 | — | — | US | disclosed |
| WO-2024259241-A1 | 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Transneural Therapeutics, Inc. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| WO-2022159644-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2019-06-18 | — | — | US | disclosed |
| EP-1465889-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9550793-B2 | Spirocyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-01-24 | — | — | US | disclosed |
| US-9550793-B2 | Spirocyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-01-24 | — | — | US | disclosed |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2016-08-11 | — | — | US | disclosed |
| US-7354934-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-7354932-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2008-04-08 | — | — | US | disclosed |
| US-20070225269-A1 | Use of (3-(1-(3-Phenyl-Propenyl)-Piperidin-4-Yl)-2,3-Dihydro-Indol-1-Yl)-(Pyridin-4-Yl)-Methanonone Derivatives and Related Compounds as Insecticides | SYNGENTA CROP PROTECTION, INC. | 2007-09-27 | — | — | US | disclosed |
| EP-1732385-A1 | USE OF (3-(1-(3-PHENYL-PROPENYL)-PIPERIDIN-4-YL)-2,3-DIHYDRO-INDOL-1-YL)-(PYRIDIN-4-YL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INSECTICIDES | Syngenta Participations AG (CH) | 2006-12-20 | — | — | EP | disclosed |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2006-05-11 | — | — | US | disclosed |
| WO-2005058035-A1 | USE OF (3-(1-(3-PHENYL-PROPENYL)-PIPERIDIN-4-YL)-2,3-DIHYDRO-INDOL-1-YL)-(PYRIDIN-4-YL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INSECTICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| EP-1465889-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | AnorMED Inc. (CA) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2004-01-29 | — | — | US | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
| WO-2003055876-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | ADORA1 647/4885ESR2 1489/4885NR1H2 369/4885 |
| US-10322111-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | ADORA1 647/4885ESR2 1489/4885NR1H2 369/4885 |
| US-20060100240-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | ADORA1 647/4885ESR2 1489/4885NR1H2 369/4885 |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | FOXM1, MDM2, FOXO1 | ADORA1 1384/4885ESR2 321/4885NR1H2 449/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | ADORA1 1691/4885ESR2 534/4885NR1H2 333/4885 |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | ADORA1 647/4885ESR2 1489/4885NR1H2 369/4885 |
| US-20160228413-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | ADORA1 647/4885ESR2 1489/4885NR1H2 369/4885 |
| US-20040019058-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | ADORA1 647/4885ESR2 1489/4885NR1H2 369/4885 |
| US-20070225269-A1 | Use of (3-(1-(3-Phenyl-Propenyl)-Piperidin-4-Yl)-2,3-Dihydro-Indol-1-Yl)-(Pyridin-4-Yl)-Methanonone Derivatives and Related Compounds as Insecticides | CHRM1, NPY1R, MRM1 | ADORA1 340/4885ESR2 2588/4885NR1H2 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.